2016 Results preview
We expect net sales of €744mn (+8.6%), total income €836mn (+8.7%) in-line with the company’s guidance, €222mn EBITDA (+8.1%) and recurrent EBIT of €130mn (–1.0%).
PTP should decline –29.6% to €122mn reflecting lower profits from disposals than in 2015 and €121mn (–8.6%) for the Net profit. The results should be seen as a positive as they confirms the operating turnaround seen from 2Q16.
Less positive extraordinary items than in 2015 should undermine the headline profit.
Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.
Bankinter S.A. is a Spanish brokerage firm established in 1989. The company's line of business includes the provision of market research and trading services for Equity and Fixed Income products.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.